Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3420856 | 0.86 | PTGS2 (0.53) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL24896301 | 0.81 | PTGS2 (0.44) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL25215204 | 0.79 | BCL2L1 (0.51) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL3420849 | 0.79 | PTGS2 (0.49) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL24896307 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL25067951 | 0.78 | PTGS2 (0.42) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL22428759 | 0.78 | PTGS2 (0.42) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL10058349 | 0.78 | BCL2L1 (0.50) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL1497714 | 0.77 | PTGS2 (0.44) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL1113744 | 0.77 | BCL2L1 (0.52) | PTGS2PTGS1BCL2L1BCL2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023288103-A1 | METHODS FOR PREPARING LIPOSOMAL FORMULATIONS | CELATOR PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288100-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | CELATOR PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BIOVENTURES, LLC | 2020-10-22 | — | — | US | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2017101851-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BCL2, BAX, BCL2L1 | PTGS2 887/4885PTGS1 1479/4885BCL2L1 3/4885 |
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | PTGS2 2272/4885PTGS1 2097/4885BCL2L1 3463/4885 |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | ACAT1, ARSA, GLA | PTGS2 2272/4885PTGS1 2097/4885BCL2L1 3463/4885 |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | PTGS2 887/4885PTGS1 1479/4885BCL2L1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.